	US 12,265,091 B2
	Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
Donna J. Edmonds, Richmond, VA (US); Timothy E. Van Meter, Richmond, VA (US); and NaZanin Mirshahi, Richmond, VA (US)
Assigned to BRAINBOX SOLUTIONS, INC., Richmond, VA (US)
Filed by BRAINBOX SOLUTIONS, INC., Richmond, VA (US)
Filed on Oct. 8, 2021, as Appl. No. 17/497,776.
Application 17/497,776 is a division of application No. 16/313,501, granted, now 11,143,662, previously published as PCT/US2017/039991, filed on Jun. 29, 2017.
Claims priority of provisional application 62/510,187, filed on May 23, 2017.
Claims priority of provisional application 62/357,079, filed on Jun. 30, 2016.
Prior Publication US 2022/0026448 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); G01N 33/573 (2006.01); G16H 50/30 (2018.01)

CPC G01N 33/6896 (2013.01) [G01N 33/573 (2013.01); G16H 50/30 (2018.01); G01N 2800/28 (2013.01); G01N 2800/56 (2013.01)]

13 Claims

1. A method of measuring the levels of biomarker proteins in a biological sample from a human patient that has or is suspected of having a brain injury, the method comprising:

(a) measuring levels of biomarker proteins Neurogranin (NRGN) and Synuclein Beta (SNCB) in the biological sample;

(b) detecting a changed level of NRGN, and a changed level of SNCB relative to reference levels; and

(c) administering treatment for a brain injury when an increased level of NRGN and a decreased level of the SNCB is detected.